SCHEMBL20614941

SCHEMBL20614941

COC(=O)c1cc2c(s1)-c1ncc(F)cc1NCC2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.44
L3MBTL1 Q9Y468 4/20 0.44
ALDH1A1 P00352 4/20 0.44
HPGD P15428 4/20 0.44
GAA P10253 3/20 0.41
GLA P06280 3/20 0.41
ATM Q13315 2/20 0.41
RAB9A P51151 2/20 0.41
MAPT P10636 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
MAPK1 P28482 3/20 0.36
TSHR P16473 1/20 0.36
CASP1 P29466 1/20 0.36
CASP7 P55210 1/20 0.36
HSD17B10 Q99714 1/20 0.36
NPC1 O15118 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NOTUM Q6P988 3/20 0.34
PTGS1 P23219 1/20 0.34
PTGS2 P35354 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20619706 0.80 KDM4E (0.56) KDM4EL3MBTL1ALDH1A1HPGDGAA
SCHEMBL20614949 0.77 KDM4E (0.43) KDM4EL3MBTL1ALDH1A1HPGDGAA
SCHEMBL20618262 0.77 ALDH1A1 (0.48) KDM4EL3MBTL1ALDH1A1HPGDGAA
SCHEMBL20618257 0.74 KDM4E (0.40) KDM4EL3MBTL1ALDH1A1HPGDGAA
SCHEMBL20622387 0.73 KDM4E (0.68) KDM4EL3MBTL1ALDH1A1HPGDGAA
SCHEMBL20614760 0.70 ALDH1A1 (0.54) KDM4EL3MBTL1ALDH1A1HPGDGAA
SCHEMBL20614775 0.70 NOS3 (0.36)
SCHEMBL20599149 0.68 KDM4E (0.57) KDM4EL3MBTL1ALDH1A1HPGDGAA
SCHEMBL20414234 0.68 MEN1 (0.38) KDM4EL3MBTL1ALDH1A1HPGDGAA
SCHEMBL13550064 0.66 KDM4E (0.66) KDM4EL3MBTL1ALDH1A1HPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10851115-B2 Heterocyclic compounds as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2020-12-01 US disclosed
WO-2019006291-A1 HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2019-01-03 WO disclosed
US-20190002478-A1 HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. 2019-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190002478-A1 HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS SIRT1, FURIN, SIRT5 KDM4E 1342/4885L3MBTL1 4774/4885ALDH1A1 721/4885
US-10851115-B2 Heterocyclic compounds as RSV inhibitors SIRT1, FURIN, SIRT5 KDM4E 1342/4885L3MBTL1 4774/4885ALDH1A1 721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.